(no / 1621 IN THE UNITED TES PATENT AND TRADEMARK OFF Atty Dkt. 2818-93 In re Patent Application C# M# FANTO et al. Group Art Unit: 1621 RECEIVED

GROUP 1700 MAR 2 6 2003 Examiner: Barts Serial No. 09/533,381 Date: March 26,2003 March 22, 2000 Filed: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE Title: PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR **AUTOIMMUNE PATHOLOGIES** Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the signature thereon.

☒ Correspondence Address Indication Form Attached.

MAR 3 1 2003

| Fees are attached as calculated below: Total effective claims after amendment 4 minus highest number | TECH CEN | ITER 1 | 600 2900 |
|--|-------------|--------|----------|
| previously paid for 20 (at least 20) = 0 x \$ 18.00 | , | \$ | 0.00 |
| Independent claims after amendment previously paid for 3 (at least 3) = 0 x \$84.00 | | \$ | 0.00 |
| If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) | | \$ | 0.00 |
| Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months) | | \$ | 0.00 |
| Terminal disclaimer enclosed, add \$ 110.00 | | \$ | 0.00 |
| First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) Please enter the previously unentered , filed Submission attached | | \$ | 0.00 |
| | Subtotal | \$ | 0.00 |
| If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith | | -\$ | 0.00 |
| Rule 56 Information Disclosure Statement Filing Fee (\$180.00) | | \$ | 0.00 |
| Assignment Recording Fee (\$40.00) | | \$ | 0.00 |
| Other: | | | 0.00 |
| TOTAL F | EE ENCLOSED | \$ | 0.00 |

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.


1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

ARC:eaw

NIXON & VANDERHYE P.C.

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature:



American

In re Patent Application of

FANTO et al.

Atty. Ref.: 2818-93

ARECEIVED
MAR 2 8 7003

Serial No. 09/533,381

Group: 1621

GROUP 1700

Filed: March 22, 2000

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE

PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY

AND/OR AUTOIMMUNE PATHOLOGIES

March 26, 2003

RECEIVED

Assistant Commissioner for Patents Washington, DC 20231

TECH CENTER 1600/2900

Sir:

AMENDMENT

Responsive to the Official Action dated December 31, 2002, please amend the above-identified application as follows: